Strategic Focus Clinical-stage biopharma targeting first-in-class serine hydrolase inhibitors with CNS targets, presenting opportunities for partnerships in rare or high-need neurological conditions and potential co-development discussions with larger players in the CNS space.

Acquisition & Funding Former subsidiary of Lundbeck acquired in 2019 for 250M, indicating a track record of strategic exits and potential alignment with acquirers or investors seeking complementary serine hydrolase programs.

Partnership History Prior collaboration with Tourette Association of America and ongoing CNS program exploration suggests openness to patient-group collaborations and potential for joint development or research funding opportunities in CNS disorders.

Resource Constraints Small team (11-50 employees) with relatively modest revenue and early-stage funding, signaling a need for external partnerships, CRO/CMO services, and co-development models to accelerate clinical milestones.

Global Footprint Dual-location presence in Princeton and La Jolla with a global development mindset, offering potential for cross-site collaborations, access to West Coast and East Coast biotech ecosystems, and international partnering conversations.